Christopher A Eide Selected Research

DCC-2036

11/2011	The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
5/2011	The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.
1/2011	Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christopher A Eide Research Topics

Disease

28	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2021 - 03/2007
24	Neoplasms (Cancer) 01/2021 - 07/2006
12	Leukemia 01/2022 - 04/2008
11	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 07/2006
5	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2021 - 07/2010
5	Philadelphia Chromosome 10/2019 - 01/2008
4	Hematologic Neoplasms (Hematological Malignancy) 12/2019 - 01/2016
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 01/2008
2	Blast Crisis (Blast Phase) 01/2021 - 04/2017
2	Polycythemia Vera 01/2020 - 01/2018
2	Disease Progression 01/2017 - 01/2011
2	Adenocarcinoma of Lung 01/2016 - 11/2013
2	Lung Neoplasms (Lung Cancer) 01/2016 - 11/2013
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2015 - 11/2013
1	Juvenile Myelomonocytic Leukemia 01/2018
1	Splenomegaly 01/2018
1	Medulloblastoma 10/2017
1	BCR-ABL Negative Atypical Chronic Myeloid Leukemia (Leukemia, Myeloid, Philadelphia Negative) 02/2016
1	Chronic Neutrophilic Leukemia 02/2016
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2016
1	Renal Cell Carcinoma (Grawitz Tumor) 12/2015
1	Carcinogenesis 11/2014
1	Myeloid Leukemia (Leukemia, Myelocytic) 04/2014
1	Glioblastoma (Glioblastoma Multiforme) 11/2013
1	Cholangiocarcinoma 11/2013
1	Hodgkin Disease (Hodgkin's Disease) 01/2008
1	Genetic Translocation (Chromosomal Translocation) 01/2008

Drug/Important Bio-Agent (IBA)

25	Phosphotransferases (Kinase)IBA 01/2020 - 07/2006
14	Imatinib Mesylate (Gleevec)FDA Link 09/2014 - 03/2007
11	Tyrosine Kinase InhibitorsIBA 01/2021 - 11/2011
9	Pharmaceutical PreparationsIBA 01/2022 - 10/2009
6	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020 - 04/2008
6	ponatinibIBA 10/2019 - 11/2009
6	Dasatinib (BMS 354825)FDA Link 01/2016 - 11/2009
4	nilotinib FDA Link 12/2011 - 11/2009
3	venetoclaxIBA 01/2022 - 01/2016
3	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 01/2018
3	Oncogene Proteins (Oncogene Protein)IBA 01/2019 - 04/2014
3	Proteins (Proteins, Gene)FDA Link 01/2017 - 11/2013
3	DCC-2036IBA 11/2011 - 01/2011
2	ibrutinibIBA 01/2020 - 05/2018
2	CrizotinibIBA 01/2016 - 11/2013
2	Anaplastic Lymphoma KinaseIBA 09/2015 - 06/2015
2	Tyrosine (L-Tyrosine)FDA Link 05/2008 - 07/2006
1	Mitogen-Activated Protein Kinase 14IBA 01/2022
1	doramapimodIBA 01/2022
1	Sorafenib (BAY 43-9006)FDA Link 01/2022
1	p38 Mitogen-Activated Protein KinasesIBA 01/2022
1	Aurora Kinase AIBA 11/2021
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2021
1	Adenosine Triphosphatases (ATPase)IBA 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	NF-kappa B (NF-kB)IBA 01/2021
1	Erythropoietin FDA Link 01/2020
1	RNA (Ribonucleic Acid)IBA 12/2019
1	snake venom protein C activatorIBA 01/2019
1	crenolanibIBA 01/2019
1	Adenosine Triphosphate (ATP)IBA 01/2019
1	idelalisibIBA 05/2018
1	BiguanidesIBA 01/2018
1	Metformin (Glucophage)FDA LinkGeneric 01/2018
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2018
1	Protein Tyrosine PhosphatasesIBA 01/2018
1	Biological ProductsIBA 04/2017
1	Drug CombinationsIBA 01/2017
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2017
1	Interleukin-1 (Interleukin 1)IBA 01/2017
1	ruxolitinibIBA 02/2016
1	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 02/2016
1	cabozantinibIBA 01/2016
1	Bcl-2-Like Protein 11IBA 01/2016
1	SolventsIBA 01/2016
1	src-Family KinasesIBA 12/2015
1	tyrosine receptor (receptor, tyrosine)IBA 12/2015
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 11/2014
1	Protein Phosphatase 2 (Protein Phosphatase 2A)IBA 04/2014
1	Cell-Penetrating PeptidesIBA 04/2014
1	GSK 1363089IBA 11/2013
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2011
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 07/2010
1	Amino Acids FDA Link 02/2009
1	Chlorambucil (Leukeran)FDA Link 01/2008
1	bcr-abl Fusion ProteinsIBA 03/2007

Therapy/Procedure

21	Therapeutics 01/2022 - 03/2008
1	Molecular Targeted Therapy 03/2007